NUPROBE

History

Year	Detail
2016	NuProbe was founded in 2016 by Yingshuang Chai, David Yu Zhang, Peng Yin, and a few others.
2018	The company has raised $11 million to continue the development of ultra-sensitive, non-invasive blood tests for the early detection of cancer and infectious diseases.
2020	NuProbe Global and CarrierGene Biotech Co. Ltd. (Suzhou, China) have been merged, and the new company will operate in the U.S. as "NuProbe Global" and the Chinese brand "Yue Er".
2020	The company has signed an agreement with Oxford Nanopore Technologies, where Oxford Nanopore has licensed NuProbe's Blocker Displacement Amplification technology globally.
2020	NuProbe announced it has entered into a collaboration agreement with QIAGEN to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy.
2020	It has Licensed Two Technologies from Rice University, Launched Nanopore AML multi-gene panel.
2020	NuProbe and Weigao Group announced a strategic collaboration to develop a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC).
2021	NuProbe launches its VarMap Pan-Cancer NGS Panel. It uses the quantitative blocker displacement amplification (QBDA) technology.
2022	Bio-Rad and NuProbe enter into an exclusive Licensing agreement for digital PCR applications.